Open AccessInhibition of Mutated, Activated BRAF in Metastatic Melanoma
Author(s) -
Keith T. Flaherty,
Igor Puzanov,
Kevin B. Kim,
Antoni Ribas,
Grant A. McArthur,
Jeffrey A. Sosman,
Peter J. O’Dwyer,
Richard J. Lee,
Joseph F. Grippo,
K. B. Nolop,
Paul B. Chapman
Publication year - 2010
Publication title -
new england journal of medicine/the new england journal of medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 19.889
H-Index - 1030
eISSN - 1533-4406
pISSN - 0028-4793
DOI - 10.1056/nejmoa1002011
Subject(s) - medicine , melanoma , rash , oncology , cohort , maculopapular rash , adverse effect , vemurafenib , cancer , progressive disease , gastroenterology , metastatic melanoma , disease , cancer research
The identification of somatic mutations in the gene encoding the serine-threonine protein kinase B-RAF (BRAF) in the majority of melanomas offers an opportunity to test oncogene-targeted therapy for this disease.